Approved Hospital Formulary
Add Formweb to your mobile device
Medications not yet evaluated by P&T are considered NON-FORMULARY. Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step!
Please be sure to document all clinical activities daily.
Please be sure to document all clinical activities daily.
Approved Hospital Formulary
Search results for:
tocilizumab
tocilizumab
- Restricted Restricted to Outpatient Medical (for Non-COVID19/CRS).
- Restricted COVID-19 Criteria for Use
- Restricted Miscellaneous Programs
- Therapeutic Interchange
| Drug Name | Form | Strength | Formulary Unrestricted | Formulary Restricted | Non-Formulary | Interchange |
|---|---|---|---|---|---|---|
| Avtozma | INJECTION, INTRAVENOUS | 20 mg/mL | ||||
| Tyenne | INJECTION, INTRAVENOUS | 20 mg/mL | ||||
| Actemra | INJECTION, SUBCUTANEOUS | 162 mg/0.9 mL | ||||
| Avtozma | INJECTION, SUBCUTANEOUS | 162 mg/0.9 mL | ||||
| Actemra | SOLUTION, INTRAVENOUS | 20 mg/mL | ||||
| Tofidence | SOLUTION, INTRAVENOUS | 20 mg/mL |
Last updated: Aug. 28, 2026
- Black Box Warning: Serious infections risk
Cytokine Release Syndrome (CRS): Tocilizumab for treatment of CRS may be ordered by Emergency Department and hospitalist prescribers. Orders are required to be placed via the HOSP Cytokine Release Syndrome (CRS) Mgmt Associated with BiTE/IEC Therapy PowerPlan. An automatic consult to Oncology will be pre-selected within the PowerPlan.
COVID-19: Due to the potential role in treatment of COVID-19 in patients with evidence of cytokine release, tocilizumab may be utilized in select patients when prescribed by Infectious Diseases or Pediatric Critical Care following Huntsville Hospital's Criteria for Use. Due to limited supply, availability of this medication is not guaranteed.
Other Indications: Tocilizumab is as restricted to outpatient use.
The tocilizumab biosimilars approved by the Committee are classified as therapeutically equivalent and interchangeable to Actemra and the other tocilizumab biosimilars for the FDA approved indications and literature supported off-label uses. The most cost-effective agent may be used in a given patient, situation, or time period.
For Updated Formulary Preferred Products (Inpatient and Outpatient): Preferred Products for Select Agents
Actemra medication guide
Reviewed: December 2023 (Tofidence) , May 2025 (Avtozma/Tyenne)
Updated: March 2024 (Inpatient Use, Tofidence), Aug 2026 (CRS updates)
Tocilizuymab-bavi (Tofidence)
Tocilizumab-bavi (Tofidence) CRS Update
Tocilizumab-anoh (AVTOZMA) Spotlight.pdf
Tocilizumab-aazg (TYENNE) Spotlight.pdf